- Sanofi (NASDAQ:SNY) inks agreement with Kiadis Pharma (OTC:KIADF), a clinical-stage biopharma developing cell-based immunotherapy products, under which SNY will make a public offer to acquire the entire share capital of Kiadis for €5.45/share, representing an aggregate adjusted equity value of €308M.
- “We believe the Kiadis ‘off the shelf’ natural killer (NK) cell technology platform will have broad application against liquid and solid tumors, and create synergies with Sanofi’s emerging immuno-oncology pipeline, providing opportunities for us to pursue potential best-in-disease approaches,” said John Reed, M.D., Ph.D., Global Head of R&D at Sanofi.
- Kiadis’ NK cell-based medicines will be developed alone and in combination with Sanofi’s existing platforms.
- n July 2020, Sanofi licensed Kiadis’ pre-clinical K-NK004 program for potential combination for multiple myeloma.
- Subject to the completion of the offer, the company will provide the resources and capabilities necessary to accelerate the development of current Kiadis programs.
- https://seekingalpha.com/news/3629439-sanofi-to-acquire-kiadis-for-308m
Monday, November 2, 2020
Sanofi to acquire Kiadis for €308M
Siemens Healthineers AG reports FQ4 results
- Siemens Healthineers AG (OTC:SEMHF): FQ4 Non-GAAP EPS of €0.48; GAAP EPS of €0.42.
- Revenue of €3.88B (-6.3% Y/Y)
- Press Release
- https://seekingalpha.com/news/3629455-siemens-healthineers-ag-reports-fq4-results
Novartis' Aimovig shows superior tolerability, efficacy in late-stage migraine study
- Novartis (NYSE:NVS) announces that HER-MES, the first Phase IV, randomized, double-dummy, study of Aimovig (erenumab) against topiramate, an anticonvulsant, in patients with episodic and chronic migraine met its primary and secondary endpoints.
- The results showed that Aimovig had a superior tolerability and efficacy profile than topiramate, with less discontinuation over the course of the 24-week treatment phase.
- Aimovig also demonstrated superior efficacy, with a greater proportion of patients achieving at least 50% reduction in their monthly migraine days (MMDs).
- The safety profile in the HER-MES study was generally consistent with those seen in previous Aimovig clinical trials.
- The study enrolled 777 adult patients suffering from ≥ 4 MMDs.
- Additional findings and detailed results will be presented at an upcoming scientific congress.
- Novartis and Amgen (NASDAQ:AMGN) are co-commercializing Aimovig in the US. The Companies inked deal in September 2015 to develop and commercialize neuroscience treatments.
- https://seekingalpha.com/news/3629470-novartis-aimovig-shows-superior-tolerability-and-efficacy-in-late-stage-migraine-study
Eagle Pharmaceuticals EPS beats by $0.88, beats on revenue
- Eagle Pharmaceuticals (NASDAQ:EGRX): Q3 Non-GAAP EPS of $1.17 beats by $0.88; GAAP EPS of $0.51 beats by $0.49.
- Revenue of $49.93M (+21.3% Y/Y) beats by $2.95M.
- Press Release
- https://seekingalpha.com/news/3629493-eagle-pharmaceuticals-eps-beats-0_88-beats-on-revenue
Horizon Therapeutics Q3 top-line up 90%, bottom-line up 172%; hikes FY20 guidance
- Horizon Therapeutics (NASDAQ:HZNP) Q3 results:
- Revenues: $636.4M (+89.7% Y/Y) vs consensus of $531.11M.
- Tepezza ((teprotumumab-trbw)) Q3 net sales of $286.9M.
- Orphan and Rheumatology Segment: Krystexxa: $108.5M (+9%); Ravicti: $64.6M (+8%); Procysbi: $43.1M (+7%); Actimmune: $28.3M (+2%); Buphenyl: $3.2M (+6%); Quinsair: $0.2M (-23%).
- Net income: $292.8M as compared to $18.2M prior year; income/share: $1.31 as compared to $0.09M prior year; non-GAAP Net Income: $392.2M (+216%); non-GAAP EPS: $1.74 (+172%) vs consensus of $0.97.
- Non-GAAP EBITDA: $329.8M (+153%).
- CF Ops: $108.9M.
- Cash and cash equivalents of $1.73B.
- 2020 Guidance: Revenues: $2.12B - 2.14B increased from $1.85B - 1.90B vs consensus of $1.95B; Non-GAAP EBITDA: $920M - 940M from $725M - 775M; Tepezza sales: >$800M from previous guidance of >$650M.
- https://seekingalpha.com/news/3629554-horizon-therapeutics-q3-top-line-up-90-and-bottom-line-up-172-raises-fy20-guidance
Fusion Pharma teams up with AstraZeneca in next-gen radiopharmaceuticals for cancer
- Fusion Pharmaceuticals (NASDAQ:FUSN) will collaborate with AstraZeneca (NASDAQ:AZN) to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for cancer.
- The partnership will leverage Fusion's Targeted Alpha Therapies (TATs) platform and know-how in radiopharmaceuticals with AstraZeneca's portfolio of antibodies and cancer therapeutics, including DNA damage response inhibitors.
- Under the terms of the deal, the parties will discover, develop and commercialize novel TATs based on Fusion's Fast-Clear linker technology with AZN's oncology antibodies. In addition, they will explore certain combo strategies between TATs, including Fusion's lead candidate FPI-1434, and AZN's therapeutics for the potential treatment of a range of cancers. Both companies will retain full rights to their respective assets.
- AZN will pay fusion an upfront fee, milestones and other payments. Specific financial terms remain confidential.
- Fusion will host a conference call this morning at 8:30 am ET to discuss the collaboration.
- https://seekingalpha.com/news/3629545-fusion-pharma-teams-up-astrazeneca-in-next-gen-radiopharmaceuticals-for-cancer
Novartis' Kisqali extends survival in late-stage breast cancer study
Novartis (NYSE:NVS) announces that the Phase 3 MONALEESA-7 trial evaluating Kisqali (ribociclib), combined with endocrine therapy, in pre- and postmenopausal women with advanced/metastatic HR+/HER2- breast cancer met the overall survival (OS) endpoint, the first CDK4/6 inhibitor to demonstrate a statistically significant OS effect in these patients.
KISQALI is indicated in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. In pre/perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone agonist. KISQALI® is also indicated in combination with fulvestrant for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy or following disease progression on endocrine therapy.
Subscribe to:
Posts (Atom)